The present invention provides: an anticancer drug having, as an active ingredient, a bispecific antibody that contains, in a domain including an antibody variable region that binds to glypican-3 and a domain including an antibody variable region that binds to a T-cell receptor complex, a common L chain capable of improving affinity for both antigens； and a pharmaceutical composition that includes the bispecific antibody as an active ingredient and that is for concomitant use with another anticancer drug. The bispecific antibody is a novel and highly-safe molecule having high production efficiency, as well as strong antitumor activity and excellent pharmacokinetics, which is expected to be applied to various cancers.本發明提供一種抗癌劑，包括能夠使含有會結合於Glypican3之抗體可變區之域與含有會結合於T細胞受體複合體之抗體可變區之域對於兩抗原之親和性提高之有共通L鏈的雙專一性抗體作為有效成分，並提供以該雙專一性抗體作為有效成分之用於和其他抗癌劑併用的醫藥組合物。該雙專一性抗體有高產生效率，且係具有強抗腫瘤活性及安全性與優良之藥物動力學的新分子，期待適用在各式各樣的癌。
